Big Pharma Split Corp Class A Cash Flow-to-Debt Ratio
Big Pharma Split Corp Class A cash flow-to-debt ratio. Big Pharma Split Corp Class A (PRM) has a Cash Flow-to-Debt Ratio of -0.07x as of June 2026, meaning its operating cash flow of CA$-1.04 Million could theoretically repay 0% of its total liabilities (CA$14.04 Million) in one year. Check PRM cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Big Pharma Split Corp Class A (2017–2025)
Cash flow-to-debt ratio of Big Pharma Split Corp Class A from 2017 to 2025. Historical debt coverage capacity for Big Pharma Split Corp Class A across 9 annual periods. Check Big Pharma Split Corp Class A investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Big Pharma Split Corp Class A Cash Flow-to-Debt Ratio by Year (2017–2025)
Big Pharma Split Corp Class A cash flow-to-debt ratio by year from 2017 to 2025. Year-by-year debt coverage analysis for Big Pharma Split Corp Class A. For the full cash flow conversion analysis, see Big Pharma Split Corp Class A (PRM) cash conversion ratio.
| Year | CF-to-Debt Ratio | Operating CF (CAD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.08x | CA$-1.06 Million | CA$13.57 Million | ▲ +24.3% |
| 2024 | -0.10x | CA$-1.30 Million | CA$12.62 Million | ▼ -109.2% |
| 2023 | 1.11x | CA$11.86 Million | CA$10.68 Million | ▲ +1804.8% |
| 2022 | 0.06x | CA$1.13 Million | CA$19.37 Million | ▲ +110.0% |
| 2021 | -0.58x | CA$-9.00 Million | CA$15.41 Million | ▼ -230.9% |
| 2020 | 0.45x | CA$4.35 Million | CA$9.75 Million | ▼ -44.1% |
| 2019 | 0.80x | CA$8.68 Million | CA$10.87 Million | ▲ +829.5% |
| 2018 | 0.09x | CA$1.27 Million | CA$14.79 Million | ▲ +103.8% |
| 2017 | -2.24x | CA$-30.95 Million | CA$13.81 Million | — |